Close
  • Home

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

Funding

Deals  ·  Weekly Digest 15 Feb to 21 Feb 2025
Radiance Biopharma enters exclusive license for ROR-1 targeted Antibody Drug Conjugate (ADC)

Weekly Digest – February 2025 Weekly Digest – February 2025 19 Feb 2025: Radiance Biopharma enters exclusive license for ROR-1 targeted Antibody Drug Conjugate (ADC) Radiance Biopharma has signed an exclusive license agreement with CSPC Megalith for the development and […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest 15 Feb to 21 Feb 2025
Sonnet BioTherapeutics unveils ADC Platform with promising preclinical results and partnership opportunities

Weekly Digest – February 2025 Weekly Digest – February 2025 19 Feb 2025: Sonnet BioTherapeutics unveils ADC Platform with promising preclinical results and partnership opportunities Sonnet BioTherapeutics announced its ADC platform, leveraging its FHAB domain for flexible payload capacity and […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest 15 Feb to 21 Feb 2025
Myris Therapeutics is developing ultra-high DAR ADCs to enable novel precision medicine treatments for cancer

Weekly Digest – February 2025 Weekly Digest – February 2025 20 Feb 2025: Myris Therapeutics is developing ultra-high DAR ADCs to enable novel precision medicine treatments for cancer Myris Therapeutics, formerly BioHybrid Solutions, has emerged from stealth with a focus […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest 08 Feb to 14 Feb 2025
U.S. FDA approves Pfizer’s ADCETRIS combination regimen for the treatment of relapsed/refractory diffuse large B-cell lymphoma

Weekly Digest – February 2025 Weekly Digest – February 2025 12 Feb 2025: U.S. FDA approves Pfizer’s ADCETRIS combination regimen for the treatment of relapsed/refractory diffuse large B-cell lymphoma The FDA approved ADCETRIS (Brentuximab vedotin) for treating adult patients with […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest 08 Feb to 14 Feb 2025
OnCusp Therapeutics receives FDA Fast Track Designation for CUSP06 for the treatment of platinum-resistant ovarian cancer

Weekly Digest – February 2025 Weekly Digest – February 2025 12 Feb 2025: OnCusp Therapeutics receives FDA Fast Track Designation for CUSP06 for the treatment of platinum-resistant ovarian cancer The FDA granted Fast Track Designation to OnCusp Therapeutics’ lead program, […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest 08 Feb to 14 Feb 2025
DAAN Biotherapeutics signs antibody exclusive licensing agreement with LigaChem Biosciences for ADC therapeutic development

Weekly Digest – February 2025 Weekly Digest – February 2025 13 Feb 2025: DAAN Biotherapeutics signs antibody exclusive licensing agreement with LigaChem Biosciences for ADC therapeutic development DAAN Biotherapeutics signed an exclusive licensing deal with LigaChem Biosciences for a tumor-targeting […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest 08 Feb to 14 Feb 2025
IDEAYA announces further Gilead sciences clinical study collaboration evaluating combination of Trodelvy and IDE397 in MTAP-deletion NSCLC

Weekly Digest – February 2025 Weekly Digest – February 2025 13 Feb 2025: IDEAYA announces further Gilead sciences clinical study collaboration evaluating combination of Trodelvy and IDE397 in MTAP-deletion NSCLC The combination targets two complementary mechanisms in MTAP-deletion solid tumors, […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest 08 Feb to 14 Feb 2025
Ellipses In-Licences first in class novel Immuno-oncology agent with potential as a next generation checkpoint inhibitor

Weekly Digest – February 2025 Weekly Digest – February 2025 11 February 2025: Ellipses In-Licences first in class novel Immuno-oncology agent with potential as a next generation checkpoint inhibitor Ellipses Pharma will develop GENA-104 (EP0089), a first-in-class monoclonal antibody targeting […]

by Sandhya Ramalingam

Continue Reading
Clinical  ·  Weekly Digest 08 Feb to 14 Feb 2025
Pfizer and Astellas’ PADCEV (enfortumab vedotin-ejfv) plus KEYTRUDA (pembrolizumab) shows long-term efficacy in first-line treatment of locally advanced or metastatic urothelial cancer (la/mUC)

Weekly Digest – February 2025 Weekly Digest – February 2025 10 Feb 2025: Pfizer and Astellas’ PADCEV (Enfortumab vedotin) plus KEYTRUDA (pembrolizumab) shows long-term efficacy in first-line treatment of locally advanced or metastatic urothelial cancer (la/mUC) The EV-302 trial (KEYNOTE-A39) […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest 01 Feb to 07 Feb 2025
Datopotamab deruxtecan recommended for approval in the EU by CHMP for patients with previously treated metastatic HR-positive, HER2-negative breast cancer

Weekly Digest – February 2025 Weekly Digest – February 2025 31 Jan 2025: Datopotamab deruxtecan recommended for approval in the EU by CHMP for patients with previously treated metastatic HR-positive, HER2-negative breast cancer Datopotamab deruxtecan has been recommended for approval […]

by Sandhya Ramalingam

Continue Reading
« First‹ Previous525354555657585960Next ›Last »
Page 56 of 63


Contact:

  info@ciscientists.com

 +1-908-212-7484

Optimal Dose

For a subscription, please provide your email id